ReviewFrontiers in neurology2023
Miller Fisher syndrome: an updated narrative review.
Review in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Unilateral ophthalmoplegia in anti-GQ1b antibody syndrome: case report and systematic literature review.Frontiers in immunology · 2025Pooled it
- Guillain-Barre syndrome in patients receiving chimeric antigen receptor T-cell therapy: an individual participant data meta-analysis.Frontiers in neurology · 2025Pooled it
- Cerebellar ataxia in the Philippines: a scoping review of reported cases and practical approach.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- U1 Small Nuclear Ribonucleoprotein Autoantibodies Reflect the Disruption of the Blood-Nerve Barrier in Guillain-Barré Syndrome.International journal of molecular sciences · 2026Article
- Autoimmune Diseases and the Vestibular and Oculomotor System: Clinical Presentation, Diagnosis, and Treatment.Journal of eye movement research · 2026Review
- Postinfectious polyneuritis cranialis: A case report.The Journal of international medical research · 2026Article
- Article
- Miller Fisher Syndrome With Guillain-Barré Syndrome Overlap in a 20-Month-Old Girl: A Case Report.Cureus · 2026Article
- Lessons from a Severe Case of Fulminant Guillain-Barré Syndrome: A Case Report.Reports (MDPI) · 2026Article
- Miller Fisher syndrome: a case report and review of the literature.Journal of medical case reports · 2026Review
- Cytomegalovirus-Associated Parainfectious Miller Fisher Syndrome Without Anti-GQ1b Antibodies: A Case Report.The Neurohospitalist · 2026Article
- Miller Fisher Syndrome in Morocco: A 14-Year Retrospective Study of 27 Cases at a Tertiary Neurology Center.Cureus · 2026Article
- Anti-GQ1b-Positive Miller Fisher Syndrome Following Pfizer Bivalent COVID-19 Vaccination.Cureus · 2026Article
- Fusion of molecular mimicry, epigenetic predisposition, and new onset GBS: a narrative review of current understanding and future directions.Annals of medicine and surgery (2012) · 2026Review
- A Review of Essential Oils with Anti-Foods (Basel, Switzerland) · 2026Review
- Anti-GQ1b Antibody Syndrome: A Clinician-Oriented Perspective on Diagnostics, Therapy, and Atypical Phenotypes-With an Illustrative 16-Case Institutional Series.Journal of clinical medicine · 2026Review
- Serum Galectin-3 as a biomarker in acute inflammatory polyradiculoneuropathies: a cohort study.Journal of neurology · 2026Article
- Clinical spectrum and prognostic features of patients seropositive for anti-GD1a antibody.Frontiers in immunology · 2026Article
- Miller Fisher Variant of Guillain-Barré Syndrome Presenting With Dysphagia and Ophthalmoplegia.Cureus · 2026Article
- Autonomic Dysfunction in Miller Fisher Syndrome: Paralytic Ileus and Isolated Internal Ophthalmoplegia.Internal medicine (Tokyo, Japan) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Miller Fisher syndrome (MFS) is considered a rare variant of Guillain-Barré syndrome (GBS), a group of acute-onset immune-mediated neuropathies characterized by the classic triad of ataxia, areflexia, and ophthalmoparesis. The present review aimed to provide a detailed and updated profile of all aspects of the syndrome through a collection of published articles on the subject, ranging from the initial description to recent developments related to COVID-19. Methods: We searched PubMed, Scopus, EMBASE, and Web of Science databases and gray literature, including references from the identified studies, review studies, and conference abstracts on this topic. We used all MeSH terms pertaining to "Miller Fisher syndrome," "Miller Fisher," "Fisher syndrome," and "anti-GQ1b antibody." Results: An extensive bibliography was researched and summarized in the review from an initial profile of MFS since its description to the recent accounts of diagnosis in COVID-19 patients. MFS is an immune-mediated disease with onset most frequently following infection. Anti-ganglioside GQ1b antibodies, detected in ~85% of patients, play a role in the pathogenesis of the syndrome. There are usually no abnormalities in MFS through routine neuroimaging. In rare cases, neuroimaging shows nerve root enhancement and signs of the involvement of the central nervous system. The most consistent electrophysiological findings in MFS are reduced sensory nerve action potentials and absent H reflexes. Although MFS is generally self-limited and has excellent prognosis, rare recurrent forms have been documented. Conclusion: This article gives an updated narrative review of MFS with special emphasis on clinical characteristics, neurophysiology, treatment, and prognosis of MFS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.